source
- AbbVie and Genmab's Epkinly shows positive combo results, moving toward label expansion in DLBCLAbbVie and Genmab reported that their bispecific antibody Epkinly achieved a successful outcome when tested together with a commonly used cancer therapy. The data indicate that the combination was…
- Sarepta receives FDA decision deadline for exon-skipping therapies, appoints Anna Protopapas as Flare CEOThe U.S. Food and Drug Administration has set a deadline for a decision on Sarepta Therapeutics' exon‑skipping drug program, with the agency expected to rule by the end of February. The timing is…